ストックスクリーナーアプリを入手
4.28
4.04%
-0.18
前日終値:
$4.46
開ける：
$4.45
24時間の取引高:
193.80K
Relative Volume:
0.65
時価総額：
$172.89M
収益：
-
当期純損益:
$-58.75M
株価収益率:
-0.9891
EPS:
-4.327
ネットキャッシュフロー:
$-50.79M
1週間 パフォーマンス:
-6.55%
1か月 パフォーマンス:
+2.15%
6か月 パフォーマンス:
+36.31%
1年 パフォーマンス:
+67.84%
1日の値動き範囲:
$4.17
$4.45
1週間の範囲:
$4.155
$4.76
52週間の値動き範囲:
$1.91
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
名前
Onkure Therapeutics Inc
セクター
電話
(720) 307-2892
住所
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.28 | 172.89M | 0 | -58.75M | -50.79M | -4.327 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-30 | 開始されました | Evercore ISI | Outperform |
| 2024-12-05 | 開始されました | Leerink Partners | Outperform |
| 2024-10-10 | 開始されました | Oppenheimer | Outperform |
| 2023-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-12-14 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 開始されました | William Blair | Outperform |
| 2023-08-28 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-03 | 開始されました | BofA Securities | Buy |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2022-01-27 | 開始されました | Robert W. Baird | Outperform |
| 2021-12-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-22 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-05-04 | 開始されました | Jefferies | Buy |
| 2021-05-04 | 開始されました | Piper Sandler | Overweight |
| 2021-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Onkure Therapeutics Inc (OKUR) 最新ニュース
ETFs Investing in OnKure Therapeutics, Inc. Class A Stocks - TradingView
Enterprise value to EBITDA forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 - The Manila Times
OnKure lines up July 15 virtual event on cancer-drug design - Stock Titan
OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to Russell 2000 Index - marketscreener.com
OnKure Therapeutics, Inc.(NasdaqGM:OKUR) added to Russell Small Cap Completeness Index - marketscreener.com
OnKure Therapeutics, Inc.(NasdaqGM:OKUR) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
OnKure Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:OKUR) - TradingView
OKUR Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC) - The Globe and Mail
OnKure Therapeutics president and CEO sells $378 in stock By Investing.com - Investing.com Nigeria
OnKure Therapeutics president and CEO sells $378 in stock - Investing.com
OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock - Investing.com
Form 4 Onkure Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria
OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock By Investing.com - Investing.com Nigeria
[Form 4] OnKure Therapeutics, Inc. Insider Trading Activity - Stock Titan
OnKure Therapeutics (OKUR) CFO auto-sells shares to cover RSU tax withholding - Stock Titan
Onkure Therapeutics Inc (OKUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Onkure Therapeutics Inc (OKUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKUR Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline - newsline.com
Onkure Therapeutics Inc (OKUR) Institutional Confidence - TradingKey
OnKure Therapeutics Sees Volatile Trading Amid Recent Developments - timothysykes.com
OKUR Q1 2026 Earnings: EPS Miss by 46.55% Signals Aggressive Pipeline InvestmentEarnings Revision Upgrade - newsline.com
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Stock Edges HigherWeak Earnings Momentum - dars.gov.et
OnKure Therapeutics (OKUR) director receives 7,650 stock options grant - Stock Titan
OnKure Therapeutics (OKUR) director awarded 1,275 stock options at $4.30 strike - Stock Titan
Director at OnKure (NASDAQ: OKUR) receives 7,650 stock options - Stock Titan
OnKure (OKUR) awards director 7,650 stock options at $4.30 - Stock Titan
OnKure (OKUR) director receives 7,650 options at $4.30 strike - Stock Titan
OnKure (OKUR) director awarded 7,650 stock options at $4.30 strike - Stock Titan
Onkure Therapeutics patents new PI3Kα mutant inhibitors - BioWorld News
OKUR Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue StageSlow Growth Warning - newsline.com
OnKure Shareholders Approve Amended 2024 Equity Incentive Plan - The Globe and Mail
OnKure Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
OnKure (NASDAQ: OKUR) holders back equity plan changes and board slate - Stock Titan
OnKure Therapeutics (OKUR) Holds Steady Near Support: Can $4.43 Resistance Be Breached?Breakout Confirmation - newsline.com
OKUR Q1 2026 Earnings: EPS Miss of 46.6% Highlights Early-Stage R&D CostsGuidance Upgrade Report - thelegaladvocate.com
OnKure Therapeutics (OKUR) Advances 2.55% as Stock Holds Above Key SupportBollinger Expansion - The Legal Advocate
OKUR Q1 2026 Earnings: Wider EPS Loss Underscores Heavy R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Surprise Stocks - newsline.com
[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
OKUR Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEarnings Stability Report - The Legal Advocate
OKUROnKure Therapeutics Inc Stock Price and Quote - Finviz
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineMargin Guidance - The Legal Advocate
Survey finds most Boulder residents satisfied with quality of life - BizWest
Onkure Therapeutics Inc (OKUR) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):